dm+d

Unassigned

New Medicines

Focal-onset seizures in patients with drug-resistant epilepsy

Information

New molecular entity
UCB Pharma
UCB Pharma

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Jul 20Development discontinued [6].

Category

First-in-class inhibitor of seizure activity by presynaptic modulation of all three SV2 isoforms and postsynaptic enhancement of GABA‐mediated inhibition [2].
The prevalence of active epilepsy is 5-10 cases per 1,000 - but with 5-30% of these misdiagnosed as having epilepsy [1].
Focal-onset seizures in patients with drug-resistant epilepsy
Oral

Trial or other data

Mar 20UCB announces that the PIIb ARISE study did not reach statistical significance on either of its two primary endpoints. The company will analyse the results further and evaluate its impact on the DUET study [5].